Mark joined OrbiMed in 2012 and is a Partner on the Credit and Royalty team, focused on structured finance and royalty investments across healthcare sectors. Prior to joining OrbiMed, he was an Associate in investment banking at UBS, focused on leveraged finance transactions. Before UBS, Mark was an analyst at Macquarie Capital, focused on principal investments. Mark holds a B.S. in Chemistry and Biology from Duke University.